NPI registry status
Active
2026 NPPES data Neurology Physician NPI 1942697297
Verify on CMS → Matthew McAdams
Neurology Physician in Burlington, Massachusetts.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 20,467 in Neurology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
669
Medicare Part D claims · 137 beneficiaries · Neurology Physician avg: 1K
Generic prescribing
54%
generic claims · 46% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
91.4/100
▲ 8 pts above national avg 83.5 · Exceptional
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Matthew McAdams reported a CMS MIPS final score of 91.4/100 - above the 83.5 national average - and filed 669 Medicare Part D claims in 2024.
- 91.4/100
- MIPS score · +8 vs avg
- 669
- Part D claims, 2024
- 54%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Matthew McAdams
Federal records show an active NPI with both Medicare prescribing volume and a measured CMS quality score — objective registry data, not patient reviews.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1942697297), first enumerated 04/23/2015.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 669 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
CMS quality reporting (MIPS)
Reported a CMS MIPS final score of 91.4/100 in the Quality Payment Program — a federal quality measure, not a patient review.
Source: CMS Quality Payment Program
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- State context
State board disciplinary context
Massachusetts statewide board action statistics are published annually — these figures describe aggregate state activity, not Matthew McAdams's individual license status. Verify directly with the state medical board.
Source: BORIM annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1942697297 · Neurology Physician
NPI-10 · ENUM-MID · TAX-MID · MIPS-ABOVE · RX-LIGHT · BOOK-LIGHT · PHOTO-FINISH
- NPI-10 1942697297
- ENUM-MID 2015
- TAX-MID 20K Neurology Physician
- MIPS-ABOVE 91.4/100
- RX-LIGHT 669
- BOOK-LIGHT 910 in Massachusetts
- PHOTO-FINISH Joy Burke, MD · ±0.0
MIPS final-score neighbourhood
Same-specialty nationwide peers by CMS final score, not geographic proximity
- McAdams · this p…
McAdams · this provider
91.4 MIPS pts
- Thuy An Hoang-Ti…
Thuy An Hoang-Tienor, MD
91.4 MIPS pts
- Joy Burke, MD · …
Joy Burke, MD
91.4 MIPS pts
- Scott Bundlie, M…
Scott Bundlie, MD
91.4 MIPS pts
- Erin Golden, MD …
Erin Golden, MD
91.4 MIPS pts
What this shows Nearest measured MIPS peers for this NUCC specialty (2023 performance year).
Matthew McAdams's MIPS score vs every measured U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure. Clinicians whose score CMS assigned without scoring any category are excluded.
91 ≥ 61st percentile 61% of 454,083 measured providers are in lower value bands
Each bar is a band; taller bars hold more measured providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative whole-score-point band: it counts only measured clinicians in lower score bands. A CMS MIPS metric is not a recommendation or a clinical-quality rating by PlainDoctor. See methodology § corpus placement.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Matthew McAdams sits
This provider among neurology physician peers
Across the 5,099 neurology physician providers who report both Medicare Part D prescribing and a MIPS quality score, Matthew McAdams writes more Part D claims than 41% of them and scores higher on MIPS quality than 65% - placing this provider in the lower-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Each dot is one neurology physician peer from a representative sample of 60; the gold marker is Matthew McAdams. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Matthew McAdams practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Matthew McAdams?
High performer (top quartile)Primary specialty
Neurology Physician
Medicare Part D claims
669 51% vs specialty avg
MIPS final score
91.4/100 7.9 pts vs avg
Specialty distribution in Massachusetts
How Neurology Physician compares to other specialties among Massachusetts providers
Medicare quality performance, MIPS
Matthew McAdams's 2023 MIPS final score plotted against the Neurology Physician national average
- MIPS Final Score
- 91.4/100
- vs 83.5 national avg · 2023 performance year
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1942697297 |
|---|---|
| Specialty | Neurology Physician |
| Gender | Male |
| NPI Issued | 04/23/2015 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
91.4157
Final Score
Measured-score avg: 83.5
76.877
Quality
100
Promoting Interoperability
Reporting: Alternative Payment Model
License & disciplinary context - Massachusetts BORIM 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~38K Massachusetts medical licensees in 2023 - they are NOT specific to Matthew McAdams. To verify Matthew McAdams's current license status, search the BORIM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
80
Total board actions, Massachusetts 2023
Across 78 cases
2.11
Actions per 1,000 licensees
Massachusetts statewide rate
probation
Most common action type
29 cases
BORIM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Massachusetts disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Matthew McAdams - brand share 46.0%
Neurology Physician average
46% brand-name claims vs 54% generic, on 669 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
669
Total Claims
$3.0M
Total Drug Cost
137
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,152.333
- Total Day Supply
- 33,927
- Brand vs Generic
- 46% brand / 54% generic
- Brand Drug Cost
- $2.9M
- Generic Drug Cost
- $75K
Patient Demographics
- Average Patient Age
- 65.6 years
- Avg HCC Risk Score
- 1.70
- Gender Split
- 71% female / 29% male
- Age Distribution
- <65: 46, 65-74: 68, 75-84: 23, 85+: 0
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Matthew McAdams prescribes most
Top Medicare Part D drugs by claim count, 2024
- Kesimpta Pen
Kesimpta Pen
256 claims
- Baclofen 80
Baclofen
80 claims
- Duloxetine Hcl 40
Duloxetine Hcl
40 claims
- Gabapentin 28
Gabapentin
28 claims
- Modafinil 19
Modafinil
19 claims
- Copaxone 15
Copaxone
15 claims
- Fluoxetine Hcl 14
Fluoxetine Hcl
14 claims
- Glatiramer Acetate 14
Glatiramer Acetate
14 claims
| Drug | Claims |
|---|---|
| Kesimpta Pen Ofatumumab | 256 |
| Baclofen | 80 |
| Duloxetine Hcl | 40 |
| Gabapentin | 28 |
| Modafinil | 19 |
| Copaxone Glatiramer Acetate | 15 |
| Fluoxetine Hcl | 14 |
| Glatiramer Acetate | 14 |
| Tizanidine Hcl | 14 |
| Mayzent Siponimod | 13 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Neurology Physician Overview
How Matthew McAdams fits within the Neurology Physician landscape nationally.
20,467
Neurology Physician Providers in US
54
States with Neurology Physician
1,356
Avg Claims per Provider
Matthew McAdams's 669 claims are below the specialty average of 1,356.
Nationwide Neurology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for McAdams, both outside Massachusetts so the neighborhoods are not geographic containment.
Similar MIPS final score
Nearest same-specialty clinicians by CMS MIPS final score (91.4 here).
Same NPPES enumeration year (2015)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Neurology Physician Providers in Massachusetts
Other clinicians with the same primary specialty enrolled in Massachusetts, drawn from the same CMS NPPES roster as McAdams.
One of 910 Neurology Physician providers enrolled in Massachusetts, 5 are shown here.
Bardia Abbasi
Boston, MA
Dr. Shabbir Abbasi
M.D.
Leominster, MA
Dr. Lobna Abdelwahab
MD
Fall River, MA
Dr. Widad Abou Chaar
MD
Boston, MA
Dr. Mahmoud Abu-Ata
M.D.
Boston, MA
Compare Neurology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Matthew McAdams's specialty? ▼
Matthew McAdams specializes in Neurology Physician and practices in Burlington, Massachusetts.
How much does Matthew McAdams prescribe under Medicare Part D? ▼
In 2024, Matthew McAdams wrote 669 Medicare Part D claims totaling $3.0M in drug costs for 137 beneficiaries.
What is Matthew McAdams's Medicare quality score? ▼
Matthew McAdams has a CMS MIPS Final Score of 91.4/100 (Quality: 76.9). The average MIPS Final Score across the 454,083 clinicians with at least one published category score is 83.5; clinicians whose score CMS assigned without scoring any category are excluded from that average. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Matthew McAdams located? ▼
Matthew McAdams is located at 41 MALL ROAD, Burlington, MA, 01805. Phone: (781) 744-8000.
What is Matthew McAdams's NPI number? ▼
Matthew McAdams's National Provider Identifier (NPI) is 1942697297, issued on 04/23/2015.
Does Matthew McAdams prescribe more brand-name or generic drugs? ▼
Matthew McAdams's prescribing is 46% brand-name and 54% generic drugs by claim count, with $2.9M in brand drug costs.
How many Neurology Physician providers are there in the US? ▼
There are 20,467 Neurology Physician providers across 54 states in the US. The average Neurology Physician provider writes 1,356 Medicare Part D claims per year.
What drugs does Matthew McAdams prescribe most often? ▼
Based on 2024 Medicare Part D data, Matthew McAdams's most frequently prescribed drugs include Kesimpta Pen, Baclofen, Duloxetine Hcl. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Matthew McAdams accept Medicare? ▼
Matthew McAdams appears in CMS Medicare data with 669 Part D claims and 137 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Matthew McAdams's credentials? ▼
Matthew McAdams's NPI is 1942697297. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.